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Abstract
Molecular classification of diseases based on multigene expression signatures is increasingly used for diagnosis, prognosis,
and prediction of response to therapy. Immunohistochemistry (IHC) is an optimal method for validating expression
signatures obtained using high-throughput genomics techniques since IHC allows a pathologist to examine gene
expression at the protein level within the context of histologically interpretable tissue sections. Additionally, validated IHC
assays may be readily implemented as clinical tests since IHC is performed on routinely processed clinical tissue samples.
However, methods have not been available for automated n-gene expression profiling at the protein level using IHC data.
We have developed methods to compute expression level maps (signature maps) of multiple genes from IHC data digitized
on a commercial whole slide imaging system. Areas of cancer for these expression level maps are defined by a pathologist
on adjacent, co-registered H&E slides, allowing assessment of IHC statistics and heterogeneity within the diseased tissue.
This novel way of representing multiple IHC assays as signature maps will allow the development of n-gene expression
profiling databases in three dimensions throughout virtual whole organ reconstructions.
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Introduction
Disease-associated changes in gene expression patterns identi-
fied by genomics and proteomics technologies often require
validation by a corroborating method for several reasons. First,
discovery-phase experimental data may be confounded by
specimen heterogeneity. High throughput genomics and proteo-
mics technologies typically rely on the solubilization of tissue
samples into liquid protein or nucleic acid preparations. While
the assumption is often made that the samples are pure
representations of a uniform disease process, each sample is
actually composed of varying mixtures of diseased and non-
diseased tissue constituents [1]. Further, there may be heteroge-
neous biomarker expression within the diseased component of a
specimen, as exemplified by intratumoral heterogeneity in the
expression of prognostic biomarkers in breast cancer [2,3]. In
clinical laboratories, assays that rely on tissue homogenization
(sometimes referred to as ‘‘grind and bind’’ assays) [4] have
largely been replaced by antibody-based cell staining methods
that are scored in a way that accounts for heterogeneity [5].
Second, initial biomarker studies may be performed using
methods not widely available, highly technically complex, or
with slow test turn-around times making them clinically
suboptimal [6]. Third, despite their exceptional utility in the
discovery phase of experimentation, data obtained using
genomics and proteomics technologies requires validation due
to data quality problems beyond the issue of tissue heterogeneity,
including misidentification of nucleic acid probes on gene
expression microarrays [7,8], non-specificity of probes [9], and
essentially unavoidable false-positive discovery rates associated
with massive multiple hypothesis testing [10]. Appropriately
powered studies to validate initial results of genomics and
proteomics studies often are lacking [6,11].
Among validation methods, IHC offers important advantages
for translational and clinical research. IHC is performed in the
context of histologically interpretable tissue sections such that
gene expression may be evaluated in specific cells (e.g., carcinoma
cells versus background stromal and benign epithelial cells), or
sub-cellular areas (nuclear versus cytoplasmic versus membrane)
[12] at the protein level under direct microscopic visualization by
a pathologist. Multiple proteins can be measured on closely
spaced adjacent tissue sections, which are often cut at 4 mm
thickness, or approximately one-third the diameter of a malignant
cell [13], such that the relationship of multiple IHC targets can
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IHC is amenable to high-throughput validation of IHC targets in
large numbers of patient samples utilizing tissue microarray
techniques. Importantly, validated IHC assays are suitable for
implementation as clinical tests since they are optimized for the
standardized method of tissue handling (typically immersion of
tissues in buffered formalin at specified time intervals followed by
processing into paraffin blocks) that are universally applied to
tissue samples in clinics, procedure rooms, radiology suites,
operating rooms, and pathology laboratories [14,15]. Indeed, it
has become a norm for molecular signatures identified by gene
expression profiling technologies to be implemented in clinical
laboratories as multigene IHC assays, with results reportable
within the rapid turn-around times expected by clinicians and
patients. In the example of diffuse large B-cell lymphoma,
prognostic biomarkers that distinguish tumors of germinal center
versus activated B-cell subtypes were initially identified by RNA
expression microarray methods [16,17,18], and later validated at
the protein level by IHC and clinically implemented as IHC
panels with results available within a one day turnaround time
[19,20,21].
Application of a gene expression signature to patient specimens
may involve the weighted summation of gene expression data to
generate a positive or negative ‘‘vote’’ toward a relevant outcome
[22], such as diseased versus non-diseased, one malignant tumor
type versus another type, prognosis of aggressive versus non-
aggressive clinical behavior of a tumor, and prediction of response
to therapy versus non-response. The magnitude of expression of
each gene comprising a signature is typically associated with a
weighting factor derived from validation data that (a) is signed
(positive or negative) depending on whether the gene is up-
regulated or down-regulated with respect to the outcome of
interest, (b) has a magnitude related to the degree to which a
gene’s expression is associated with the outcome of interest, and (c)
may correct for differences in overall immunohistochemical
staining intensity among different genes comprising the signature.
A simple n-gene ‘‘voting’’ classifier within a tissue region of
interest, S(~ r r), may be given as
S(~ r r)~
X n
i~1
wi|gene(~ r r)i, ð1Þ
where the vector~ r r denotes the spatial dimensions of the region of
interest, wi is the weighting factor, and gene(~ r r)i is the expression
level measured for each of n-genes. It should be emphasized that
IHC assays, because they are performed on tissue sections in
which architectural features are retained, allow examination of
heterogeneity of n-gene expression signatures across diseased tissue
areas. Thus, IHC preserves a spatial aspect of data that would be
lost upon tissue solubilization for standard proteomic and genomic
assays.
Although studies utilizing n-gene classifiers indicate that IHC
biomarker expression signatures hold high promise in routine
clinical practice [23], there is currently a paucity of available
methods to summate the weighted expression of multiple IHC
markers across pathologist-annotated diseased tissue areas. In
recent years, numerous manufacturers have developed whole slide
imaging (WSI) systems that convert glass slides into diagnostic
quality digital images that are readily accessible via network-
connected computers and can provide extensive features for
annotation and analysis [24]. WSI has been used in clinical
practice and teaching, including primary pathologic diagnosis
[25], second opinion consultation via telepathology [26], creation
of teaching archives [27], and quality assurance [28]. WSI has
been extensively used in research applications ranging from
detailed measurement of histologic landmarks [29,30] to quanti-
tative IHC [31]. We have developed methods integrated with a
WSI system to generate n-gene IHC expression profiles across
tissue areas electronically annotated by a pathologist on whole-
slide images. For purposes of illustration, we demonstrate the
utility of these methods by generating a putative four-gene
signature of prostate cancer aggressiveness in a representative
prostatectomy tissue block and investigate the registration
accuracy and its impact on calculated signature mapping values
in 10 prostate cancer-containing blocks of prostatectomy tissue
from unique subjects.
Materials and Methods
Genes selected
We performed IHC studies for four gene products whose
expression levels are known to be related to patient outcomes in
prostate cancer (PCa): up-regulated expression of the tumor cell
proliferation marker Ki-67 (Online Mendelian Inheritance in Man
[OMIM] [32] designation: MKI67), the marker of neuroendo-
crine tumor cell differentiation neuron-specific enolase (OMIM:
ENO2), and the microvascular marker CD34 have been
associated with poor prognosis [33,34,35,36,37,38,39,40], whereas
down-regulated expression of prostate specific acid phosphatase
(PSAP; OMIM: ACPP) is associated with higher tumor grade [41]
and unfavorable pathologic features in prostatectomy specimens
that follow diagnoses of PCa on transurethral resections [42]. It
should be stressed that these markers were chosen simply to
illustrate the developed methods and because of their availability
for the automated immunostainer; we do not mean to suggest that
the expression signature of these gene products constitutes a
validated prognostic signature.
IHC assays
After obtaining written consent from research subjects and
approval from the University of Minnesota Institutional Review
Board, unstained adjacent 4 mm sections of formalin-fixed
paraffin-embedded prostate tissue were cut from 10 prostatecto-
my blocks representing 10 unique subjects and PCa of different
histologic grades. One section was stained with hematoxylin and
eosin (H&E) and, using an automated immunostainer (Ventana
Medical Systems, Tucson, AZ), adjacent sections were stained
with primary antibodies, washed, and then a brown precipitate
was developed at sites of primary antibody binding through use of
a peroxidase-conjugated second step antibody and a 3,3-
diaminobenzidine (DAB) reagent (Bond Polymer, Leica, Rich-
mond, IL). For all ten cases, primary antibodies directed against
the protein products of MKI67 (antibody clone MM1, Leica
Microsystems, Bannockburn, IL), CD34 (QBend/10, Ventana)
and ACPP (clone PASE/4LT, Cell Marque, Rocklin, CA) were
used as they represent a wide range of staining intensities from
relatively low to medium to high, respectively. In one additional
case, used to demonstrate the creation of a four-gene signature
map, a fourth IHC slide was generated with primary antibodies
directed against the protein product of ENO2 (clone BBS/NC/
V1-h14, Covance, Princeton, NJ). IHC slides, and a final
negative control section in which primary antibody incubation
was omitted, were counterstained with hematoxylin. All slides
were cover-slipped. The negative control sections were visually
inspected by the study pathologist (SCS) who validated the
absence of DAB signal.
N-Gene Protein Expression Maps
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Slides were scanned at 206 magnification (0.560.5 mm
2 pixel
resolution) using a WSI instrument (ScanScope CS, Aperio, Vista,
CA) fitted with a 206/0.75 Plan Apo objective lens (Olympus,
Center Valley, PA). Images were saved in SVS format (Aperio)
which is essentially a TIFF compressed with JPG2000. Images
were saved on a server equipped with server software (Image-
Server, Aperio) and retrieved using file management software
(Spectrum, Aperio). Pathologist-annotated tumor regions were
drawn using a pen tablet screen (Cintiq 21UX, Wacom, Kazo-shi,
Saitama, Japan) on whole slide images viewed at high resolution
using the Aperio system’s annotation software (ImageScope 10,
Aperio). Regions of cancer were separately labeled with their
Gleason Grade (e.g. 3+3, 3+4, etc.) within different virtual planes
(‘‘layers’’) of the reference slide image file.
Generating Signature Maps
A software interface, which will be referred to as SigMap, was
written in the Java programming language [43] to generate IHC
signature maps (see Table 1 for glossary of terms) through a
multistep process described below and detailed in Figure 1. Upon
launching SigMap, existing WSI thumbnails and annotations in an
XML format were downloaded. From the list of available images,
the user selected the reference image (an H&E-stained slide image
in this example), the IHC slides to be analyzed, and the analysis
algorithm macro to be used for the antibody markers of interest
(Figure 2). The default algorithm, Positive Pixel Count (v9,
Aperio), was configured to detect the fraction of pixels that exceed
pre-set (user-adjustable if desired) weak, moderate, and strong
threshold limits in the brown colorimetric channel. If desired,
other analysis macros available to the user within Spectrum could
be selected from a drop-down menu. If present for a particular
reference slide, pathologist annotations were also downloaded for
subsequent sub-region analysis. Communication with ImageServer
for downloading annotations and imaging data is accomplished
using an HTTP GET/POST protocol provided by Aperio [44]
which also allows SigMap to initiate slide analysis using pre-
existing algorithms (Algorithm Framework, Aperio).
After downloading, the whole-slide IHC images were each
registered to the reference image (the H&E stained slide image in
this example) through a two-step process involving coarse manual
alignment followed by an automatic fine registration using a
software module called TurboReg [45,46]. During the first step in
image alignment, each IHC slide was brought into rough
alignment with the reference slide. Visually guided manipulations
were used to flip and rotate each IHC slide so that it was in rough
alignment with the reference image (Figure 3). TurboReg software
then automatically completed the registration process by mini-
mizing the mean location error through rigid body transforma-
tions (i.e. translations and rotations) (Figure 4).
Table 1. Glossary of Terms.
Reference slide Digitized slide on which annotations are drawn
IHC slide Digitized IHC-stained slide (adjacent section relative to reference slide)
IHC score Quantified IHC data at a single grid region of an image
IHC map 2D representation of IHC scores across an IHC slide
IHC signature score Multiple IHC scores summated to represent quantified IHC data at a single grid region of an image
IHC signature map Multiple IHC scores representing n-gene protein expression across the annotation area of the reference slide
doi:10.1371/journal.pone.0033520.t001
Figure 1. The workflow for generating signature maps. The
steps to generate a signature map take place on the host computer
running the interface software (labeled as SigMap) and on Aperio’s
ImageServer (labeled as Aperio). The location at which each step is
performed is defined to the left of each step. After digitizing both the
reference H&E and IHC data on the Aperio system, the data are
downloaded to SigMap. This data may include pathologist annotations
(i.e.capsuleandgradedareasofcancerinthecaseoftheprostate).Auser
defined grid (G) is then defined in SigMap on the coordinatespace of the
reference (H&E) data. The inverse of the transformation (Ti
21) required to
register each IHC image (IHCi) to the H&E is used to match G to the full
resolution IHCi data as it exists on Aperio’s ImageServer. The transformed
grid, Ti
21 (G), defines regions from which IHC values are determined
(using the pre-selected algorithm) and combined to form IHC maps. The
transformation of the IHC maps after downloading to SigMap, Ti(Mapi),
places each in the coordinate space of the reference image allowing
them to be combined into a signature map (S) using Equation 1.
doi:10.1371/journal.pone.0033520.g001
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made on the reference image using SigMap (Figure 5). In this
example, a grid with a resolution of 0.25 by 0.25 mm
2 was used.
Grid locations outside of the tissue boundary were discarded, and
SigMap was further set to discard grid locations outside of
annotation regions as determined by the Monte Carlo method
[47], in which random points (an adjustable number, by default
500 points) within each grid location were generated and tested for
whether they resided within an annotated area. If a threshold (an
adjustable percentage, by default 50%) of these points were within
the annotated area, the grid location was retained, and if not, the
grid location was discarded. Adjustment to require inclusion of
more points would lower the threshold for discarding grid locations,
and thus only retain grid locations further interior to annotations.
Additionally, the pathologist could review the IHC slides and mark
(using a ‘‘negative pen tool’’ function in ImageScope) areas of any
slide image (reference or IHC stained) that lacked diagnostic tissue,
contained artifact, etc.; SigMap would remove these negatively
selected regions from the analysis for all stains.
Using the inverse of the previously saved transformations
determined from the image alignment process, the retained grid
locations generated on the reference H&E image were trans-
formed to the native orientation of each full resolution IHC
stained image. The transformed grid locations were written to a
file in Aperio’s annotation XML format and attached to each IHC
slide by uploading to ImageServer. At each grid location, the
intensity of each IHC stain was computed (termed an IHC score)
using Positive Pixel Count as the selected analysis algorithm. The
IHC scores across an entire grid were used to generate IHC maps
after transforming back to match the reference H&E orientation.
Using gene-specific weighting values, weighted IHC scores for
the n-genes were summated across all IHC stains at the same grid
location (termed an IHC signature score) using Equation 1. In this
study, the magnitude of the weights for MKI67, EN02, CD34 and
ACPP were calculated to normalize the mean IHC score for each
stain from the regions of annotated cancer across all subjects, and
the sign of each weight reflected whether published studies cited
above suggest that these proteins are up- or down-regulated in
aggressive (relative to non-aggressive) PCa. IHC signature scores
were displayed as a two dimensional representation oriented to the
reference tissue section (termed an IHC signature map). After
completing this process, output files were recorded into a specified
folder, the grid created by SigMap was removed and the original
pathologist annotations were restored on ImageServer.
Figure 2. The main SigMap program window. Within the main program window the user selects the reference H&E image (designated ‘‘Select
H&E’’), the IHC images, and the analysis macro to be used. The Aperio Positive Pixel Count algorithm was employed in this example using default
threshold settings (designated as ‘‘Default Brown Staining PPC’’). If desired, threshold settings may be adjusted by navigating to the algorithm
settings menu by selecting ‘‘Set Algorithm Settings’’.
doi:10.1371/journal.pone.0033520.g002
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process alternated between Aperio and SigMap software environ-
ments. Processes which required the full resolution data
(0.560.5 mm
2), such as defining regions of disease and algorithm
analysis, were performed on Aperio, whereas downsampled data
were used within SigMap for registration, grid definition and
signature map generation. There were two reasons to separate the
tasks in this manner. First, performing image manipulations in the
WSI system would be highly computationally intensive, since the
uncompressed images averaged 5.4 GB for the ten cases in this
study whereas the size of the 0.56images used in SigMap were an
average size of 3.4 MB (20620 mm
2). Second, the functionality to
register digitized slides and create signature maps did not exist on
WSI systems. Thus SigMap performed manipulations on the lower
resolution data in SigMap and imposed manipulations on the high
resolution source data via transformed analysis grids applied in the
Aperio system.
Assessment of Registration Performance
In order to evaluate the performance of the signature mapping
software and the effect of registration errors on IHC map and IHC
signature map statistics, gold standard registrations were per-
formed using Photoshop (version CS5 Extended, Adobe, San Jose,
CA). This optimal registration was accomplished by visually
matching each IHC image to its reference H&E image with
particular attention to the regions of annotated cancer. These pre-
registered data were uploaded onto the Aperio server and
signature mapping was performed as described above but without
any additional registration steps. These data are referred to as the
benchmark data and, for the purposes of this study, represent the
best registration achievable. The same cases were also processed
with SigMap with the slides in their native scanned orientations,
allowing the user and TurboReg to register the digitized IHC to
the reference H&E data as described in the methods section
(referred to as the native data).
Three IHC slides for each of 10 cases were used to assess
registration performance and the impact on generated IHC
Signature values over regions of annotated cancer. To quantify the
registration accuracy, five landmarks, distributed across the image,
were placed on each native IHC image and at corresponding
spatial locations on the reference H&E based on prevalent
anatomic features. The error was assessed for each IHC image
by calculating the vector distance between the reference H&E and
native IHC image in all 150 resulting pairs of landmarks using
standard tools in Photoshop. The vector lengths between the
reference and native landmarks were recorded as the registration
error (in micrometers).
The generated IHC signature scores were produced for each
annotated region of cancer. Box plots indicating minimum, first
quartile, median, third quartile and maximum values of the
signature scores from each annotated cancer region were used to
display IHC signature score data for both the benchmark and the
native data.
Results
Signature Map Generation
The IHC scores across the entire grid shown in Figure 5 were
used to generate IHC maps for all four genes after transforming
back to match the reference H&E orientation (Figure 6). IHC
Figure 3. SigMap’s registration window. Shown is the registration window in which the user performs rough alignment of each IHC slide (the
section stained with antibody directed against ACPP illustrated to the right) to the reference slide (H&E stained section illustrated to the left).
Manipulations may include clockwise or counterclockwise rotations in 90 degree increments, or vertical or horizontal flipping to achieve rough image
alignment prior to launching TurboReg which is done by selecting ‘‘OK’’.
doi:10.1371/journal.pone.0033520.g003
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locations and the results of all processed grid locations were
displayed as an IHC signature map (Figures 6 and 7). The weights
used for generating the signature map were 21.0, 19, 4 and 4 for
ACPP, CD34, MKI67 and ENOS, respectively. The weights for
ACPP, CD34 and MKI67 were generated using all annotated
cases while the weight for ENOS was derived from the single case
for which that stain was performed.
The approximate time to generate a signature map depends on
the number of IHC slides included, the complexity of the required
annotations and the area over which IHC scores are to be
generated. The total time to generate the IHC signature map
shown in Figure 7 was approximately 64 minutes: 35 minutes to
digitize 5 slides; 4 minutes to annotate the reference H&E;
2 minutes to connect to the server, select slides, stains and analysis
algorithms in SigMap; 1 minute for registration and grid
generation; 20 minutes to analyze of for all 4 IHC slides
(5 minutes per slide); and 1 minute for generating final results.
Registration Analysis
The error calculated for all 150 landmark pairs, color coded by
protein, is shown in the histogram in Figure 8. Stains had similar
skewed error distributions with (median mm, maximum mm) values
of (114, 317), (88, 350), and (94, 398) for MKI67 (low intensity
stain), (CD34 medium intensity staining) and ACPP (high intensity
staining), respectively. Median errors of 88–114 mm correspond to
6–7 cell diameters, and the maximal error of 398 mm corresponds
to 27 cell diameters, assuming a malignant PCa cell diameter of
15 mm [13]. There was no apparent relationship between staining
intensity and error in registering IHC images with reference H&E
images.
Effect of Registration Method on Signature Map Data
To evaluate the effect of registration method on IHC signature
maps, IHC signature maps were generated for 10 cases using a
benchmark method and compared with IHC signature maps
generated using the SigMap method of initial manual course
registration followed by TurboReg fine registration. Data for IHC
signature scores within 11 annotated cancer regions were available
for these ten cases (one case had two distinct areas of cancer in the
reference H&E image), and are presented in Figure 9 as box plots
for the benchmark (blue) and the native (red) IHC signature values
from these regions. The signature scores from the native data,
which underwent the registration procedure of SigMap, closely
match the optimally registered results from the benchmark data.
Therefore, registration error associated with manual course
registration followed by TurboReg fine registration appears to
have essentially no impact on signature scores within annotated
regions of cancer.
Discussion
Methods to generate maps of n-gene biomarker signatures
within pathologist-annotated tissue regions were developed by
combining the functionality of a Java software interface, SigMap,
with that of a commercial digitization platform, Aperio. By itself,
the Aperio system provides diagnostic quality digitization,
annotation tools and analysis functionality, but there was no way
to combine multiple IHC and H&E data sets. Signature maps, as
described in this paper, provide a unique insight into the spatial
distribution of gene signatures which has the potential to extend
the research and diagnostic potential of immunohistochemistry
studies.
Figure 4. Alignment results using TurboReg. (A) Image of H&E-stained reference section image. (B) Image of section stained for ACPP
previously brought into rough alignment with reference image by user. (C) Image of section stained for ENO2 previously brought into rough
alignment with reference image by user. (D) Monochromatic images of A–C generated for purposes of overlay illustrations. (E) TurboReg translated
and rotated (angle ﬁA) the image of ACPP-stained section until a mean location error was minimized. (F) Similarly, TurboReg translated and rotated
(angle ﬁB) the image of ENO2-stained section to minimize mean location error between this image and the reference H&E-stained image. The final
registered IHC image is overlaid on the reference H&E image in the bottom of panels (E) and (F). Values for translations and rotation determined by
TurboReg along with the initial coarse registration steps were stored in the software for later use in transforming grid locations from the reference to
the IHC images when generating IHC and signature maps.
doi:10.1371/journal.pone.0033520.g004
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There are several factors which can potentially impact the
signature scores generated by SigMap including the weights used
for combining the multiple IHC datasets, consistency of IHC
staining and the analysis algorithm used for generating the IHC
score, variability in annotating cancer regions and the accuracy
of the registration procedure. In this study, while the magnitude
of the weighting factors were simply used to normalize the mean
expression level of each IHC marker, the polarity of the weights
reflected published data regarding whether each protein would
be expected to be up- or down-regulated in aggressive (versus
non-aggressive) prostate cancer. In clinical application, the sign
and magnitude of each weighting factor would be determined
through a validation study correlating expression levels with an
outcome variable, and then weighting factors would be applied
uniformly across all patient samples to allow cross-case
comparisons.
Staining consistency, stain quantification and annotation
variability may also impact the reliability of IHC signature scores.
To minimize the potential impact of variable staining and
quantification, an automated immunostainer and antibodies
optimized for use on that platform were used in this study.
However, in general, staining consistency and quantification
algorithms would need to be validated before clinical use. While
not investigated in the current study, it is expected that between
pathologists, the margins of annotated regions of cancer may vary.
The potential impact of this variability on summary statistics for
annotated regions requires subsequent study.
Registration Methods
The effect of registration on the generation of signature scores
was explicitly tested in this study. The rigid registration strategy
used in the current implementation of SigMap is very basic. This
approach minimizes the mean-square difference between the
Figure 5. Generation of an IHC Map. (A) Reference H&E-stained section. (B) Pathologist annotations drawn in XML markup format using a pen
tablet screen. In this example, prostate cancer of Gleason sum score 3+3 is outlined in green, score 3+4 is outlined in yellow and 4+3 is outlined in
red. (C) IHC Map overlaid the annotated image with a grid with dimensions 0.2560.25 mm
2.( D) Grid squares that were within pathologist annotated
areas were retained. (E) Contours of the annotated regions at the resolution of the analysis grid registered to the ACPP image. (F) The intensity of
ACPP staining within each grid location in (F) was determined by using the results of the Positive Pixel Count algorithm (default settings) multiplied
by the assigned weighting factor. The weighted value for each grid square was termed an IHC score. The two-dimensional depiction of IHC Score
values was termed an IHC Map.
doi:10.1371/journal.pone.0033520.g005
N-Gene Protein Expression Maps
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33520reference H&E and the IHC images using translations and
rotations. Using the mean-square difference to optimize the
registration process assumes that the spatial distributions and
signal intensities between the images are similar for best results.
Although the digitized slides are converted to greyscale before
registration, the distribution of signal intensities can vary widely
between the H&E and various IHC datasets. Despite this fact, this
registration method performed well as the overall anatomic
structure apparently dominates the registration yielding excellent
results. This can be appreciated by the median registration errors
of 99 mm as determined from the control points between the
benchmark and the native datasets. This registration error is
smaller than the grid resolution of 250 mm used to generate the
presented signature maps, which likely explains the negligible
Figure 6. Generation of an IHC Signature Map. Displayed values of the IHC maps and IHC signature maps are in relative units (r. u.). (A) IHC Map
for ENO2, shown in red since the weighting factor was positively signed (higher expression is associated with aggressive disease) and thus higher
expression was shown as more intense red. (B) IHC Map for CD34 (also shown in red due to positively signed weighting factor). (C) IHC Map for MKI67
(also shown in red due to positively signed weighing factor). (D) IHC Map for ACPP, shown in blue since the weighting factor was negatively signed
(higher expression is associated with non-aggressive disease) and thus higher expression was shown as more intense blue. (E) The weighted sum of
IHC Scores (termed an IHC Signature Map) were projected in grid squares across annotated tumor areas of Gleason scores 3+3, 3+4, and 4+3 outlined
in green, yellow and red, respectively.
doi:10.1371/journal.pone.0033520.g006
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reported in Figure 9.
The image alignment method could be further improved by
automating the process and by potentially implementing deform-
able registration methods to address tissue compression and
stretching which occurs when making slides. For example, Cooper
et al. have demonstrated an automatic non-rigid, feature-based
strategy to register histological sections with different stain types
[48]. However, it is unclear how such methods would perform
when large rotational differences are present or when IHC sections
are flipped with respect to the reference H&E.
While alternative registration strategies are possible within
SigMap, there are some limitations as to what can be realized on
the Aperio system. Each grid location on Aperio must be defined
by a series of straight edges which connect at vertices. Therefore, if
deformable registration strategies are used to match the IHC data
to the reference H&E, the subsequent grid made from these
transformations could only be approximated. In general, these
transformations should also be invertible.
Processing time
Most of the total time required for generating signature maps is
spent on processes which run in the background. Out of the
64 minutes it took to generate the signature map in Figure 7,
35 minutes were spent scanning the H&E and IHC slides and
20 minutes on analysis which is performed on the ImageServer.
The amount of pathologist time is minimal and limited to the time
required to annotate the digitized H&E (approximately 4 minutes
per slide), while the other laboratory staff time to setup slides for
scanning and run SigMap is minimal (approximately 10 minutes).
Newer WSI imaging platforms are several-fold faster than the
study instrument. Further, the analysis time on the ImageServer
could be greatly reduced by either fully utilizing multi-core
processing or GPU acceleration since the process to analyze the
IHC score within each grid location is highly parallelizable.
Potential Role of IHC Signature Maps
N-gene expression profiling has broad applicability in anatomic
pathology as new diagnostic, prognostic, and predictive protein
biomarker panels are developed to individualize approaches to
patient care. Compared to single gene models, multigene
expression profiles of cancer and other complex diseases may
Figure 7. Four-gene IHC signature map. The IHC signature map is
displayed in relative units (r. u.), projected against a black background
to illustrate the four-gene signature map in each pathologist-annotated
area (tumor areas of Gleason sum scores 3+3, 3+4, and 4+3 outlined in
green, yellow and red, respectively).
doi:10.1371/journal.pone.0033520.g007
Figure 8. Registration errors between the IHC and H&E images. Registration errors between each of the 3 IHC datasets registered to the
reference H&E data for all 10 subjects. The error estimate is based on the vector distance between landmarks placed on the same anatomic features
present in the registered IHC and reference H&E slides. The histogram contains 5 measurements for each of 3 IHC datasets for 10 cases resulting in a
total of 150 error estimates. The histogram shows the stain dependent errors for ACPP (blue), MKI67 (red) and CD34 (green).
doi:10.1371/journal.pone.0033520.g008
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and predict response to therapy. In prostate cancer, numerous
publications have identified n-gene molecular signatures that are
correlated with biochemical failure versus non-failure following
prostatectomy [49,50,51,52,53,54].
Validation of n-gene expression signatures may be best
performed using IHC. Several recent papers suggest that n-gene
expression profiling assessed at the protein level by IHC are
amenable to large-scale, tissue microarray-based validation
studies, which yield similar tumor sub-typing as multigene
signatures assessed by molecular (qRT-PCR or microarray)
methods [55,56]. IHC has been used to validate the association
of gene expression profiles in prediction of cancer patient response
to treatment [57], and prognosticating risk of metastasis [23,58]
and other outcome measures [59]. Once validated, IHC-based
assays may be rapidly deployed as clinical tests [19,20,21] on
standardly fixed and processed tissue sections, with rapid (typically
same-day) turn-around times optimal for clinical practice.
Formalin fixation and paraffin embedding of tumor tissues have
been recently reinforced by the College of American Pathologists
and the American Society of Clinical Oncology as being reliable
for generating reproducible intra- and inter-laboratory measure-
ments of gene expression levels [14,15].
Alternatives to using signature maps for multigene signature
analysis include laser capture microdissection of tissue sub-regions
followed by solubilization of captured tissues for multigene
molecular analysis [60]. However, the signature maps constructed
by SigMap much more directly addresses gene expression in tissue
sub-regions without need for tissue microdissection and allow the
assessment of expression heterogeneity. Another alternative is
immunofluorescence, which allows staining with multiple anti-
bodies, each labeled with a distinct fluorescent marker [61,62].
Signature maps are superior to immunofluorescence results for
two reasons. Routine colorimetric IHC with hematoxylin
counterstaining allows bright-field determination of tissue archi-
tecture under pathologist direct visualization that is superior to
dark field methods used in immunofluorescence [63,64]. Further,
whereas special optimization procedures often needed to multiplex
fluorescently-labeled antibody assays, SigMap allows signature
determination from multiple, routine, single antibody staining
assays.
The benefits of evaluating biomarker expression under direct
microscopic visualization in the context of histologically inter-
pretable tissue sections, rather than ‘‘grind and bind’’ methods
such as those used in most biochemical experiments including
most genomics and proteomics methods, is perhaps best
illustrated by the history of estrogen receptor (ER) quantitation
in breast cancer. Although ER quantification was initially
performed by solubilizing snap-frozen tumor tissue and then
using tissue extracts in biochemical ligand binding assays (LBA),
IHC assays rapidly replaced biochemical assays. IHC allows the
pathologist to restrict analysis only to visualized tumor cells (small
ER-positive tumors may otherwise yield false-negative LBA
results due to damping of signal by abundant benign background
tissue elements), is less expensive, is amenable to standardized
tissue handling methods, and allows direct correlation with other
molecular markers assayed on adjacent sections (reviewed in
references [65,66,67]).
Figure 9. IHC signature scores from 11 annotated regions of cancer from 10 subjects. The benchmark (blue) and native (red) data for the
same region are shown immediately adjacent to each other for comparison. For each region, the minimum, 1
st quartile, median, 3
rd quartile and the
maximum values are shown. The data are sorted first by grade and then by the median of the benchmark data within each grade.
doi:10.1371/journal.pone.0033520.g009
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multigene signature expression within diseased tissue areas is an
additional strength of signature maps. Heterogeneity in HER-2
amplification occurs in 5–30% of breast cancer tumors [68] and
there is also considerable spatial heterogeneity in HER-2 protein
expression, particularly among cases with equivocal (2+) overall
staining [69]. There is data to suggest that this heterogeneity may
be clinically important: 2–5% of women whose primary breast
tumors lacked definite HER-2 amplification or HER-2 protein (3+)
over-expression nevertheless had lymph node metastases that were
amplified/over-expressed [70], suggesting that small HER-2-
positive tumor subclones present in the primary tumor may evolve
to give rise to metastatic tumor growths. Signature maps will allow
the degree of spatial heterogeneity of single-gene expression and
multigene signatures across large tumor areas present on
pathologist annotated whole slides to be quantitatively assessed.
As such, these n-gene expression maps may be useful in studies
evaluating the potential importance of heterogeneity in patient
prognostic and predictive assays.
Finally, signature maps may be useful to develop multigene
expression signatures throughout virtually reconstructed whole
organs as they retain their spatial relationships to the H&E-stained
reference whole slide images. Using the developed methods,
transformations (flips, translations and rotations), needed to
assemble individual images into reconstructed whole organs,
may be mathematically applied to IHC signature maps in a
manner similar to the way such transformations are handled by
SigMap, such that three-dimensional multigene expression
signatures may be displayed in the spatial context of reconstructed
organ histology. Spatially co-registering virtual whole organ
reconstructions with preoperative in vivo anatomic and functional
imaging methods such as computed tomography (CT), positron
emission tomography (PET) and magnetic resonance imaging
(MRI) would then allow direct comparison in three dimensions
between features obtained by imaging and features including
multigene signatures obtained by pathologic evaluation. For
example, genes whose expression patterns are validated to be
highly significant for predicting disease aggressiveness could be co-
registered with imaging and used as a gold standard for identifying
imaging biomarkers that assess disease aggressiveness in vivo. This
would expand upon previous work in mouse models in which
spatially mapped gene expression data was overlaid on detailed
anatomic information [71,72].
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